Biotech startup raises $64 million to erase cancer it's even in the name

March 8, 2019 by Bradley J. Fikes
Credit: CC0 Public Domain

San Diego startup Erasca said recently it has raised $64 million to develop cancer therapies with the ambitious goal of eventually curing the disease.

The new funding is up from the $42 million reported in December.

New investors in privately held Erasca include ARCH Venture Partners; Andreessen Horowitz; Reneo Capital; and other private and strategic investors.

The Series A financing will support the company's plans to license new potential drugs, the company said. In addition, the money will speed completion of its AI platform. It's called OPRA, for Oncology Pattern Recognition Algorithm, and it's meant to sort through biological data to find new cancer vulnerabilities.

Dr. Jonathan Lim, executive chairman, said the company's name is short for "erase cancer." The name was deliberately chosen to signify that the company's goals are ambitious.

"We really wanted to have a huge, even audacious aspiration, given just how difficult it is, but also with the humility that it's going to take multiple approaches to be able to do so," said Lim, a longtime biotech entrepreneur.

Lim said the new financing funds Erasca's operations well into 2022. By that time, Erasca should have a in clinical testing.

Lim was CEO of San Diego biotech Ignyta, another developer of cancer treatments. He took part in its sale in December 2017 to Roche for $1.7 billion. He was also CEO of San Diego's Halozyme Therapeutics from 2003 to 2010, and co-founder of Newport Beach-based Bonti, purchased last year by Allergan for $195 million.

At Erasca, Lim said the company is studying biology, looking for potential drugs to buy and using OPRA to improve its effectiveness.

The company is now looking for drugs made of small molecules, which are usually given orally. In addition, Erasca is willing to investigate antibody drugs, which are made of large protein molecules and generally must be given by IV or injection.

The company licensed its key technology from a U.S. academic center outside of San Diego, Lim said. The now has 16 employees, and might grow to 20 by year's end.

Explore further: Roche targets tumours with Ignyta purchase


Related Stories

Roche targets tumours with Ignyta purchase

December 22, 2017

Roche, the world's top cancer drug maker, announced Friday it had agreed to buy US firm Ignyta, which is developing a treatment against some tumours, for $1.7 billion (1.4 billion euros).

Roche seals takeover of cancer data upstart Flatiron

April 6, 2018

Swiss pharmaceutical giant Roche on Friday said it has completed its acquisition of US oncology data leader Flatiron Health, a tech upstart that has runs a huge platform of cancer patient records.

Groupon raises $950 mln in new funding

January 10, 2011

Internet bargain coupon phenomenon Groupon said Monday it had raised $950 million in the past month to invest in technology, fund its global expansion and compensate company employees and early investors.

Recommended for you

Coffee-based colloids for direct solar absorption

March 22, 2019

Solar energy is one of the most promising resources to help reduce fossil fuel consumption and mitigate greenhouse gas emissions to power a sustainable future. Devices presently in use to convert solar energy into thermal ...

EPA adviser is promoting harmful ideas, scientists say

March 22, 2019

The Trump administration's reliance on industry-funded environmental specialists is again coming under fire, this time by researchers who say that Louis Anthony "Tony" Cox Jr., who leads a key Environmental Protection Agency ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.